NCT00748709 2025-02-11
Phase II Trial of BIBW 2992 (Afatinib) in Genetically Pre-screened Cancers With EGFR and/or HER2 Gene Amplification.
Boehringer Ingelheim
Phase 2 Terminated
Clinical Trials
7 trialsNCT04410653 2024-04-05
Afatinib in Advanced NRG1-Rearranged Malignancies
German Cancer Research Center
Phase 2 Completed
NCT03239015 2022-03-04
Efficacy and Safety of Precision Therapy in Refractory Tumor
Shanghai Changzheng Hospital
Phase 2 Unknown
NCT04533321 2020-08-31
A Biomarker-implemented Clinical Study Evaluating Mutations in MET and TP53 in a Population of Treatment-refractory Squamous Cell Carcinoma
National University Hospital, Singapore
Phase 2 Unknown
NCT02142036 2019-03-13
MetAction
Oslo University Hospital
Phase 2 Completed
NCT03486509 2018-04-03
Afatinib Plus Chemotherapy Against Esophageal or Lung Squamous Cell Carcinoma
Fujian Cancer Hospital
Phase 2 Unknown
NCT00875433 2013-12-30
Afatinib (BIBW 2992) QTcF Trial in Patients With Relapsed or Refractory Solid Tumours
Boehringer Ingelheim
Phase 2 Completed